Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-K _______________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-391 ...

Exhibit 99.1 LightPath Technologies Reports Fiscal 2026 Second Quarter Financial Results ORLANDO, FL – February 11, 2026 – LightPath Technologies, Inc. (NASDAQ: LPTH) ("LightPath," the "Company," "we," or "our"), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today announced financial results for its fiscal second quarter ended December 31, 2025. Financial Summary: | | | Three Months Ended December 31, | | | | --- | --- | --- | --- | --- | | $ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. (Exact name of registrant as specified in charter) Delaware 51-0354549 (State of incorporation) (I.R.S. ...

Exhibit 99.1 Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, February 11, 2026 -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2025, and provided an update on its clini ...

Confluent Announces Fourth Quarter and Fiscal Year 2025 Financial Results MOUNTAIN VIEW, Calif. -- February 11, 2026 -- Confluent, Inc. (NASDAQ: CFLT), the data streaming pioneer, today announced financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025. "Confluent delivered a strong fourth quarter to close the year, including 23% year over year growth in Confluent Cloud," said Jay Kreps, co-founder and CEO, Confluent. "Our AI product advancements and continued innovation across ...

经济观察网布鲁克菲尔德资产管理据悉正与黑石集团谈判，拟以约10亿欧元收购后者在西班牙的房地产 公司Fidere，该交易可能成为2026年西班牙房地产领域规模最大的交易之一。公司基于2025年底公告披 露，2025年12月31日启动自身云业务，通过直接租赁数据中心芯片降低AI开发成本，与亚马逊等科技 巨头竞争；该业务与100亿美元AI基金挂钩，预计2026年将看到初步运营和客户拓展。同时，2025年11 月联合英伟达和科威特投资局启动规模达1000亿美元的AI基础设施计划，2025年6月公布的瑞典100亿 美元AI投资(欧洲最大之一)预计2026年进入实施阶段。公司将于2026年2月27日除权除息，每股派息 0.5025美元，派息日为2026年3月31日。 以上内容基于公开资料整理，不构成投资建议。 机构观点 加皇资本市场于2026年2月5日维持布鲁克菲尔德资产管理买入评级，目标价74美元。 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 28, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 22-102 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41988 IB ACQUISITION CORP. (State or other jurisdiction of incorporation or organization) NEVADA 85-2946784 (I.R.S. Employer Id ...

Fourth Quarter 2025 Investor Supplement Key Financial & Metrics Highlights First Quarter and Full Year 2026 Guidance | | Q1 2026 | Full Year 2026 | | --- | --- | --- | | Total Revenue (millions) | $168.0 - $174.0 | $700.0 - $720.0 | | Non-GAAP Operating (3) Income (millions) | $14.0 - $18.0 | $50.0 - $60.0 | | Non-GAAP Net Income (4)(5) per share | $0.07 - $0.10 | $0.23 - $0.29 | Exhibit 99.2 Calculations of Key and Other Selected Metrics – Quarterly (unaudited) Product Innovation and Developments Customer ...

经济观察网科磊(KLAC.OQ)近期的股价异动主要源于其2026财年第二季度财报中披露的第三财季业绩 指引未能满足市场对AI驱动高增长的预期。尽管公司第二财季营收及调整后每股收益均超预期，但对 第三财季的指引被市场视为"增长幅度温和"，未能体现AI领域的强劲加速态势，叠加估值处于高位，触 发了短期资金调整。 股票近期走势 机构观点 花旗集团维持"买入"评级，摩根大通维持"增持"评级，认为AI基础设施和HBM需求将支撑长期增长。 但华创证券提示，尽管2026年全球晶圆厂设备市场预计增长，设备采购节奏波动可能影响短期业绩。 以上内容基于公开资料整理，不构成投资建议。 近7天科磊股价波动显著，其中2月4日单日跌3.56%，2月6日大幅反弹8.41%，2月11日收于1,483.39美 元，区间累计涨幅3.88%，振幅15.20%。异动期间成交活跃，反映市场对业绩指引的分歧。年初至今股 价累计上涨22.08%，但半导体设备板块同期涨幅为2.27%，显示个股波动偏离行业整体。 ...